Latest Industry Insights

In this interview, Dr. Kelemen discusses the advantages of lipid-based delivery systems and their potential to expand the reach of CAR T-cell therapies into solid tumor indications.

In this interview, we explore how single-cell technologies, automation and strategic partnerships are shaping the future of cancer immunotherapy.

Discover how one of the biggest biopharma acquisitions of 2025 aims to expand rare tumor therapies for hard-to-treat cancers like desmoid tumors.

In this interview, Dr. Eleonora Juarez explains how Oxford Nanopore’s new Hereditary Cancer Panel could streamline testing, expand access and influence future best practices in hereditary cancer workflows.

In the heart of Cambridge, a quiet revolution is reshaping the way science startups scale: one built not only on breakthrough molecules and patents, but also on collaborative spaces, shared values and pragmatic support.

Discover how scalable, human-based in vitro models are reshaping discovery pipelines, balancing complexity with reproducibility, and enabling new kinds of experimentation that go beyond the limits of animal research.

Dr. Jamie Spangler gives a vision of how engineered proteins could overcome the toughest challenges in cancer immunotherapy.

This article explores the unique characteristics and challenges of life sciences marketing, offering insights on how to achieve meaningful engagement with a highly specialized audience.

In this article, discover how the FDA and NIH are replacing animal testing with human models, such as organoids, featuring expert insights on safer, faster and ethical drug development.

An epigenetic analysis platform spun out of academia could address current issues with wider adoption of epigenetic profiling as a cancer diagnostic tool. Hear about the challenges, successes and importance of industry partners.